What does Interpharm Holdings, Inc. do?

Interpharm Holdings, Inc. (IPAH) operates in the Medical - Pharmaceuticals industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is IPAH's market cap?

Interpharm Holdings, Inc. (IPAH) has a market capitalization of approximately $660, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does IPAH pay a dividend?

No — Interpharm Holdings, Inc. (IPAH) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Interpharm Holdings, Inc. (IPAH) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

IPAH

Interpharm Holdings, Inc.

OTC·Medical, Pharmaceuticals · Healthcare

$0.00$0.00+0.00%

Market cap$660.00·Market closed·Aug 26 8:00 PM UTC

Price Chart

$0.00+$0.00 (+0.00%)today

−90.00%CAGR −37.07%

Select date range

FromTo

Jan 3, 2000Aug 28, 2021 → Aug 28, 2026· 5.0 yrsAug 28, 2026

Key Metrics

IPAH does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

Revenue$69.21M

Net Income−$29.36M

Net Margin−42.4%

Operating Cash Flow−$21.75M

Capital Expenditures$7.86M

Free Cash Flow−$29.61M

Return on Equity—

Return on Invested Capital−7.7%

Net Debt$38.43M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for IPAH and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how IPAH's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for IPAH and 80,000+ other tickers.

About Interpharm Holdings, Inc.

Interpharm Holdings, Inc. specializes in the formulation, manufacturing, and commercialization of generic pharmaceuticals, encompassing both prescription-strength and over-the-counter varieties. The company's medicinal products are supplied to a wide array of clients, including significant retail chains, wholesale distributors, managed healthcare organizations, and nationwide distribution networks. Established in 1984, the firm maintains its principal operations in Hauppauge, New York.

CEO: Raj Sutaria
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Exchange: OTC
Employees: 670
Website: www.interpharmusa.com

Peers

DNAPrint Genomics, Inc.

Cap

$12.9K

IMMB

Immunotech Laboratories, Inc.

Cap

$115.0K

Latest News

News Tab

No recent news available.

Frequently Asked Questions About IPAH

What does Interpharm Holdings, Inc. do?: Interpharm Holdings, Inc. (IPAH) operates in the Medical - Pharmaceuticals industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is IPAH's market cap?: Interpharm Holdings, Inc. (IPAH) has a market capitalization of approximately $660, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does IPAH pay a dividend?: No — Interpharm Holdings, Inc. (IPAH) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is IPAH profitable?: Interpharm Holdings, Inc. (IPAH) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.